TNI BioTech, Inc. has announced the signing of a letter-of-intent agreement to open and operate clinics in the Republic of Malawi, Africa, for oncology and the treatment of HIV/AIDS and other infectious diseases. The agreement falls under a joint venture agreement that the company has with GB Oncology and Imaging Group LTD (GBOIG).
There is a critical need in Malawi for HIV/AIDS and cancer treatment, with U.S. officials estimating the HIV infection rate as being approximately 10%. The UN estimates that nearly 23 million people in sub-Saharan Africa are HIV positive. 70% of new HIV infections worldwide are in sub-Saharan Africa, and 90% of HIV positive children are living in sub-Saharan Africa. Almost half of all deaths from AIDS-related illnesses in 2010 were in southern Africa.
The President of the Republic of Malawi, Joyce Banda, is a women’s rights activist who has backed aggressive HIV prevention programs. The new government has signed an agreement with GBOIG, in partnership with TNI BioTech, to provide treatments, including safer and more effective radiation, new targeted drug therapies, and minimally invasive surgical alternatives. The clinics will also support patients using patented therapies from TNI BioTech to boost the immune system. Low Dose Naltraxone (LDN) in clinical trials, both in the United States and Africa, has shown to be an effective immune system modulator without significant toxic side effects. It is non-addicting and can be administered by a single capsule once daily. IRT-103 (LDN) is also now available as a transdermal cream that is made for and is particularly effective with children suffering from a compromised immune system.
A Managing Member of GBOIG commented on the potential benefits of the treatments: “Though cultural mores change very slowly, we believe that IRT-103 (LDN) can serve to save literally millions of lives within a relatively short time at a cost of a $1.00 a day per person. This is in marked contrast to the $240 per dose for the antiretroviral drugs which must be taken several times a day, require a lot of medical supervision, and are notorious for toxic side effects and drug resistance in the patients who are fortunate enough to obtain them.”
TNI BioTech CEO, Noreen Griffin, said: “When you understand that there are millions of victims of HIV/AIDS in Africa and only 37% of the people eligible for treatment in sub-Saharan Africa received antiretroviral drug treatment in 2009 because of economics, health personnel availability, and drug availability, we felt that something had to be done.”
TNI BioTech, Inc. is a biotech company combating fatal diseases through the activation and mobilization of the body’s immune system using patented immunotherapy. Under the agreement, GBOIG and TNIB expect to have the oncology and infectious disease clinic fully operational within 12 months, and hope to begin treatment for HIV patients within 180 days of the signing of the agreement. Under the agreement, TNIB and GBOIG will begin by providing HIV/AIDS treatment to 25,000 patients and hopefully expand to 500,000 patients within two years.
For additional information, visit www.TNIBio.com
Let us hear your thoughts below: